Vestmark Advisory Solutions Inc. Trims Stock Holdings in Bristol Myers Squibb Company $BMY

Vestmark Advisory Solutions Inc. lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 53.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,420 shares of the biopharmaceutical company’s stock after selling 7,351 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Bristol Myers Squibb were worth $297,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of BMY. Brighton Jones LLC increased its stake in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in shares of Bristol Myers Squibb in the 1st quarter valued at $338,000. Massachusetts Financial Services Co. MA bought a new position in shares of Bristol Myers Squibb during the 1st quarter valued at $2,298,000. First Command Advisory Services Inc. lifted its stake in Bristol Myers Squibb by 46.1% in the first quarter. First Command Advisory Services Inc. now owns 2,545 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 803 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in shares of Bristol Myers Squibb by 1.3% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 87,928 shares of the biopharmaceutical company’s stock valued at $5,363,000 after buying an additional 1,124 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BMY has been the topic of a number of research reports. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a report on Tuesday, August 5th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Four equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $55.45.

Bristol Myers Squibb Trading Up 1.6%

NYSE:BMY opened at $49.87 on Thursday. The firm has a 50-day simple moving average of $45.31 and a 200-day simple moving average of $46.69. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The firm has a market cap of $101.53 billion, a P/E ratio of 20.05, a P/E/G ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were paid a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.0%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is 83.78%.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.